image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 8.94
-2.3 %
$ 4.42 B
Market Cap
13.15
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ELAN stock under the worst case scenario is HIDDEN Compared to the current market price of 8.94 USD, Elanco Animal Health Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ELAN stock under the base case scenario is HIDDEN Compared to the current market price of 8.94 USD, Elanco Animal Health Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ELAN stock under the best case scenario is HIDDEN Compared to the current market price of 8.94 USD, Elanco Animal Health Incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ELAN

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
4.44 B REVENUE
0.50%
251 M OPERATING INCOME
-23.01%
338 M NET INCOME
127.46%
541 M OPERATING CASH FLOW
99.63%
1.16 B INVESTING CASH FLOW
785.21%
-1.49 B FINANCING CASH FLOW
-1697.59%
1.02 B REVENUE
-0.97%
8 M OPERATING INCOME
260.00%
-8 M NET INCOME
-2.20%
177 M OPERATING CASH FLOW
9.26%
-90 M INVESTING CASH FLOW
-7.23%
-32 M FINANCING CASH FLOW
97.61%
Balance Sheet Elanco Animal Health Incorporated
image
Current Assets 3.22 B
Cash & Short-Term Investments 468 M
Receivables 886 M
Other Current Assets 1.86 B
Non-Current Assets 9.4 B
Long-Term Investments 0
PP&E 993 M
Other Non-Current Assets 8.41 B
3.71 %7.02 %14.75 %7.87 %66.64 %Total Assets$12.6b
Current Liabilities 1.32 B
Accounts Payable 296 M
Short-Term Debt 44 M
Other Current Liabilities 975 M
Non-Current Liabilities 5.2 B
Long-Term Debt 4.28 B
Other Non-Current Liabilities 926 M
4.54 %14.96 %65.62 %14.21 %Total Liabilities$6.5b
EFFICIENCY
Earnings Waterfall Elanco Animal Health Incorporated
image
Revenue 4.44 B
Cost Of Revenue 2.53 B
Gross Profit 1.91 B
Operating Expenses 1.66 B
Operating Income 251 M
Other Expenses -87 M
Net Income 338 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(3b)2b(2b)251m87m338mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.01% GROSS MARGIN
43.01%
5.65% OPERATING MARGIN
5.65%
7.61% NET MARGIN
7.61%
5.54% ROE
5.54%
2.68% ROA
2.68%
1.53% ROIC
1.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Elanco Animal Health Incorporated
image
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 338 M
Depreciation & Amortization 662 M
Capital Expenditures -147 M
Stock-Based Compensation 55 M
Change in Working Capital 149 M
Others -540 M
Free Cash Flow 394 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Elanco Animal Health Incorporated
image
Wall Street analysts predict an average 1-year price target for ELAN of $16.8 , with forecasts ranging from a low of $12 to a high of $22 .
ELAN Lowest Price Target Wall Street Target
12 USD 34.23%
ELAN Average Price Target Wall Street Target
16.8 USD 88.29%
ELAN Highest Price Target Wall Street Target
22 USD 146.09%
Price
Max Price Target
Min Price Target
Average Price Target
222220201818161614141212101088May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Elanco Animal Health Incorporated
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
484 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.35 M USD 2
6-9 MONTHS
255 K USD 1
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 2 weeks ago
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 4 weeks ago
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets GREENFIELD, Ind. , March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. prnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN. accessnewswire.com - 1 month ago
8. Profile Summary

Elanco Animal Health Incorporated ELAN

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 4.42 B
Dividend Yield 0.00%
Description Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Contact 2500 Innovation Way, Greenfield, IN, 46140 https://www.elanco.com
IPO Date Sept. 20, 2018
Employees 9000
Officers Mr. Rajeev Modi Executive Vice President of U.S. Pet Health & Global Digital Transformation Ms. Colleen Dekker Head of Global Corporate Communications Ms. Grace McArdle Executive Vice President of Manufacturing & Quality